title: [Ovarian malignant tumours. Efficacy of germ cell and sex cord tumour treatment protocol in Poland].
abstract: Approximately 1% of all malignant tumours among children are localized in the ovary. The majority belongs to germ cell tumours and occurs in the peripubertal period. AIM of the study was the evaluation of the efficacy of malignant ovarian germ cell tumour treatment programme in children.
  
  
  METHODS
  Since 1998, 40 girls with malignant ovarian tumours were enrolled in the multicentre trial. Mixed germ cell tumours with yolk sac elements and dysgerminoma occurred the most often. Alfa-fetoprotein (AFP) was increased in almost one half of patients. Tumour exceeded the ovary margin in more than half the patients and 25% were qualified as high risk group. 38 children completed the treatment. All but one patient with neuroblastoma received TGM protocol (Tumeurs Germinates Malignes). A VBP regimen (vinblastine, bleomycin, cisplatin) was applied in 19 girls, VIP regimen (etoposide, ifosfamide, cisplatin) in 16, two received no chemotherapy. Due to delayed remission after first-line chemotherapy it was prolonged with ABK (adriamycine, bleomycine, carboplatin) in 3 patients, 1 megachemotherapy regimen with autologous bone marrow transplantation was realized, one patient received a 1.5 year long oral chemotherapy. All the children underwent surgery, 34 primary (56% complete), 12 secondary (75% complete). 8 children were operated twice.
  
  
  RESULTS
  Among 34 children with germ cell tumours and 3 with sex cord tumours who completed the treatment all are alive in the first remission. 1 child with neuroblastoma localised in the ovary died due to recurrence. A median follow-up period was 42 months.
  
  
  CONCLUSIONS
  The TGM protocol appears to be highly efficient in treatment of germ cell tumours even in advanced stages.
authors.affiliation: Klinika Pediatrii, Gastroenterologii i Onkologii Dzieciecej, Akademia Medyczna, ul. Nowe Ogrody 1-6, 80-803 Gdańsk, Poland. step@amg.gda.pl
authors.forename: Stefan
authors.initials: S
authors.lastname: Popadiuk
authors.forename: Maria
authors.initials: M
authors.lastname: Korzon
authors.forename: Alicja
authors.initials: A
authors.lastname: Chybicka
authors.forename: Krzysztof
authors.initials: K
authors.lastname: Szmyd
authors.forename: Maria
authors.initials: M
authors.lastname: Dzierzega
authors.forename: Joanna
authors.initials: J
authors.lastname: Trelińska
authors.forename: Jerzy R
authors.initials: JR
authors.lastname: Kowalczyk
authors.forename: Hanna
authors.initials: H
authors.lastname: Wiśniewska-Slusarz
authors.forename: Wojciech
authors.initials: W
authors.lastname: Woźniak
authors.forename: Katarzyna
authors.initials: K
authors.lastname: Bilska
authors.forename: Jacek
authors.initials: J
authors.lastname: Wachowiak
authors.forename: Benigna
authors.initials: B
authors.lastname: Konatkowska
authors.forename: Mariusz
authors.initials: M
authors.lastname: Wysocki
authors.forename: Maryna
authors.initials: M
authors.lastname: Krawczuk-Rybak
authors.forename: Piotr
authors.initials: P
authors.lastname: Czauderna
authors.forename: Małgorzata
authors.initials: M
authors.lastname: Szumera
authors.forename: Katarzyna
authors.initials: K
authors.lastname: Sznurkowska
authors.forename: Joanna
authors.initials: J
authors.lastname: Renke
mesh_terms: D000293:Adolescent; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D001761:Bleomycin / Q000008:administration & dosage; D016026:Bone Marrow Transplantation; D016190:Carboplatin / Q000008:administration & dosage; D002648:Child; D002675:Child, Preschool; D002945:Cisplatin / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D004334:Drug Administration Schedule; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D006801:Humans; D007069:Ifosfamide / Q000008:administration & dosage; D009373:Neoplasms, Germ Cell and Embryonal / Q000188:drug therapy* / Q000473:pathology; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000473:pathology; D011044:Poland; D012074:Remission Induction; D018312:Sex Cord-Gonadal Stromal Tumors / Q000188:drug therapy* / Q000473:pathology; D016896:Treatment Outcome; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D001761:Bleomycin; D014750:Vincristine; D005047:Etoposide; D004317:Doxorubicin; D016190:Carboplatin; D002945:Cisplatin; D007069:Ifosfamide